top of page
Biotechnology Direct Investments across US, Europe, and GCC

Biotechnology Direct Investments

US, Europe and GCC
Life Sciences Growth Capital

Licorne Gulf invests direct and syndicated capital into commercial-stage biotechnology, biopharma manufacturing, and regulated diagnostic platforms across the United States, Europe, and the Gulf. We back proven revenue-generating leaders—no early-stage startups.

SECTOR FOCUS

Six Core Biotechnology Verticals

We deploy growth equity and cross-border expansion capital into scaled, clinically validated life sciences operators across the US, Europe, and GCC.

Biopharmaceuticals and Biologics Manufacturing

Biopharma and Biologics Production

We invest in commercial biologic, biosimilar, and specialty therapeutic producers with FDA/EMA regulatory approvals, validated commercial sales, and regional capacity expansion demand.

Clinical Genomics and Precision Medicine

Clinical Genomics and Precision Medicine

We back scaled genomic sequencing labs, precision oncology platforms, and population-health data systems supporting national healthcare modernization across Europe and the GCC.

Automated Diagnostics and Molecular Assays

Diagnostics and Molecular Testing

We fund high-throughput diagnostic labs, point-of-care molecular testing manufacturers, and clinical reagent suppliers serving hospital networks and sovereign health programs.

Regulated MedTech Devices and Imaging Systems

MedTech Devices and Imaging

We partner with revenue-generating medical device OEMs, surgical robotics platforms, and clinical imaging providers scaling distribution across Gulf hospital systems.

Pharmaceutical Formulation and CDMO Facilities

Pharma CDMO and Fill-Finish

We finance contract development and manufacturing organizations (CDMOs), sterile fill-finish plants, and localized pharmaceutical packaging infrastructure serving MENA demand.

Bioprocessing Reagents and Laboratory Automation

Bioprocessing and Lab Automation

We deploy capital into upstream bioprocessing consumables, cleanroom instrumentation, and laboratory automation systems powering commercial GMP life sciences production.

INVESTMENT MANDATE

Transaction Criteria & Deal Structuring

How we structure growth equity, licensing joint ventures, and strategic acquisitions linking US and European life sciences IP with Gulf healthcare capacity.

Target Company Criteria

Investment Criteria (US, Europe & GCC)

We target commercial-stage biotech, CDMO, and medtech enterprises only—never pre-revenue concept startups. Candidates must demonstrate regulatory approvals, commercial revenue, and protected IP.

GCC Market Entry

GCC Market Entry & Joint Ventures

For Western life sciences companies entering Saudi Arabia, Qatar, the UAE, and Bahrain, we structure local GMP fill-finish JVs, SFDA/regulatory pathways, and hospital procurement access.

Strategic Buyouts

Co-Investment & Strategic Buyouts

We co-invest alongside healthcare funds, family offices, pharmaceutical groups, and sovereign health entities across expansion rounds, carve-outs, and strategic buyouts.

FinTech and Institutional Payment Infrastructure

Governance & Capital Alignment

Transactions are structured under UK and Swiss institutional holding governance to align founder equity incentives with long-term value creation and clean cap-table discipline.

Industrial Automation and Smart Manufacturing Robotics

Direct Investment Committee

Every submission is evaluated directly by Licorne Gulf managing principals. Initial Mandate screening is typically completed within 5–10 business days before formal diligence.

Hyperscale Cloud and Sovereign Data Center Infrastructure

Confidentiality & IP Protection

All clinical trial dossiers, regulatory filings, patent portfolios, and financial models are evaluated strictly in-house under NDA and never shared with external brokers.

GCC VALUE CREATION

US & Europe to GCC Scale

"We pair growth capital with GMP localization and sovereign healthcare market access across Saudi Arabia, Qatar, and the UAE."

GCC governments are investing billions into domestic pharmaceutical security, precision-genomics programs, and local biologics manufacturing—creating high demand for commercial US and European life sciences platforms.

Licorne Gulf provides experienced local execution on the ground, helping scaled biotech and medtech firms navigate SFDA and GCC regulatory registration, build local manufacturing joint ventures, and win institutional tenders.

Abu Dhabi financial skyline in the GCC at dusk

20+

YEARS GLOBAL REACH

LEADERSHIP & PORTFOLIO

Executive Team & Track Record

Meet our principals across London, Geneva, Doha, Riyadh, and North America.

LG

CLIENTS & MANDATES

Global Partners & Mandates

Explore our institutional mandates, life sciences and industrial partnerships, and executive track record.

GP

FOUNDER & INVESTOR FAQ

Key Questions on Biotechnology Investments

Direct answers on investment mandate, GCC expansion support, co-investments, and confidential transaction review.

Enterprise AI and B2B Software Direct Investments

What biotech stages and companies do you target?

We invest strictly in scaled, revenue-generating biopharma, diagnostics, CDMO, and regulated medtech companies—never pre-clinical startups or unvalidated concepts.

Microelectronics, Semiconductors and Deep Tech Hardware

What transaction structures do you provide?

Licorne Gulf deploys direct growth equity, GMP facility expansion capital, co-investment tranches, licensing joint ventures, and strategic buyouts.

Cybersecurity and Critical Digital Infrastructure

Do US or European firms need GCC approvals beforehand?

No. Companies with established FDA or EMA approvals and commercial traction partner with us specifically to establish GCC distribution, SFDA registration, and local fill-finish JVs.

FinTech and Institutional Payment Infrastructure

Do you invest in pre-revenue drug discovery startups?

No. Our mandate is focused strictly on scaled commercial operators with proven revenue, regulatory clearance, and clear profitability or commercial trajectory.

Industrial Automation and Smart Manufacturing Robotics

Can healthcare funds or family offices co-invest?

Yes. We regularly co-invest alongside life sciences venture-growth funds, pharmaceutical corporates, family offices, and sovereign partners.

Hyperscale Cloud and Sovereign Data Center Infrastructure

How are clinical and IP documents kept confidential?

All proprietary technical data, clinical dossiers, and financials are reviewed exclusively inside our investment committee under NDA and UK/Swiss governance.

Submit a Biotech Investment Opportunity

If you lead a scaled, commercial life sciences, biopharma, diagnostic, or medtech enterprise seeking growth capital or GCC expansion, submit your memorandum confidentially.

bottom of page